SANOVO; front line savo osi in MET over-expressed common mEGFR; 3+ or 2+ (interesting definition); double blind with placebo control; screen 1896 to randomise 326; PFS HR 0.48 in 3+ (0.53 ITT); OS HR 0.48; mDOR 23.5m #ESMO26